SYMBRAVO (Meloxicam; Rizatriptan Benzoate) Patent Expiration, LOE Window & CMS Spending
SYMBRAVO (Meloxicam; Rizatriptan Benzoate) by Axsome Therapeutics: FDA Orange Book core substance LOE 2038-05-18 (last listed 2045-03-10), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,150 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Axsome Therapeutics |
| FDA Application & Pathway | N215431 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-05-18 |
| Last Listed Patent or Exclusivity Date | 2045-03-10 |
| Orange Book Patents (*PED Extensions) | 96 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,150 intro WAC) |